Summary.-The radiosensitizing efficiencies of 4 structural analogues of misonidazole (MISO) have been compared with that of the parent compound. Three of these were charged basic compounds, previously shown in vitro to be 10 times more efficient. Enhancement ratios were measured from pairs of tumour growth-delay curves for the mouse fibrosarcoma SA Fab. Two routes of administration and ranges of drug dose and intervals between injection and irradiation were tested.
mental tumours is profoundly influenced by the presence of naturally occurring hypoxic cells which are radio-resistant and which dominate tumour response after high single doses of X-rays (Thomlinson & Craddock, 1967) . Chemical radiosensitizers have been developed which mimic 02 as a sensitizer, and should diffuse through the tumour to the critical hypoxic cells (Adams et al., 1976) . Two of these, the 2-nitroimidazole, misonidazole (MISO), and the 5-nitroimidazole, metronidazole, have been shown to sensitize most animal tumours (for reviews see Denekamp et al., 1980a; Fowler & Denekamp, 1979 ) and are currently being tested in clinical trials throughout the world. Large drug doses are needed to achieve radiosensitization and the clinical success of these drugs is limited by their neurotoxicity and gastro-9 intestinal side effects (Coleman et al., 1982; Dische et al., 1979 Dische et al., , 1981 Dische et al., , 1982 Urtasun et al., 1975 Urtasun et al., , 1978 Wasserman et al., 1979) .
A more effective or less toxic radiosensitizer is therefore needed for use in the clinic. In vitro studies have indicated that a group of 2-nitroimidazoles with basic properties is 10 times more efficient irt vitro than MISO or its metabolite desmethylmisonidazole (Ro 05-9963) (Fig. 1 , Table I ), though only a 3-fold increase was expected on the basis of electron-affinity (Smithen et al., 1980) . It Tumour growth delay was used to measure After irradiation, tumours were measured e radiosensitizing efficiency of the 5 com-as before and growth delay was estimated ounds. The tumour was a spontaneous from the time taken for each individual )rosarcoma (SA FAb) which has been tumour to increase its size by a fixed aintained by serial transplantation in the increment, which in different experiments was rain of origin (WHT/GyfBSVS). The tum-either 3-5 or 4-5 mm GMD, corresponding to a ir has a volume-doubling time of 4 days and 4-5-fold increase in volume. The mean delay estimated hypoxic fraction of 20-50% for a dose group of 7-9 mice was then lenekamp et al., 1980a). calculated.
Tumour transplantation was performed on The pharmacology of the compounds was ,tches of 100-150 female WHT mice, aged studied using mice of the same age, weight, -12 weeks. Under penthrane anaesthesia, sex and strain, bearing tumours 6-7 mm in mour fragments (0.5 mm diameter) were diameter. Mice were killed by decapitation planted s.c. on the chest or back using a and blood samples were collected from the )car.
neck into heparinized tubes. The brain was When the tumours became palpable they removed and the tumour dissected free of skin re measured with vernier calipers 3 times a and s.c. connective tissue. The tissue samples ek in 3 orthogonal diameters. When the were placed on ice and kept at 4C throughout ometric-mean diameter (GMD) reached subsequent processing. The tissues were 7 mm the mice were randomly allocated to weighed and homogenized in 4-9 vols of ferent treatment groups. The latent period distilled water. A suitable aliquot of these and us [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] days and at the time of irradiation of blood was taken and vortex mixed with an e mice weighed 26-31 g.
internal standard (10 ,ug Ro 07-0913). MethIrradiations were performed using 240kV anol (1-2 ml) was added to precipitate protein Three of the drugs were administered at an equimolar dose of 2-5 ,umol/g. Ro 03-8799 was administered at the maximum tolerated dose of 1P7 ,tmol/g. Ro 31-0054 is not shown because it was too toxic to test at comparable doses (i.v. LD50= 0 7 ,umol/g). Fig. 3(a) shows the time course of drug concentrations in tumours, measured by HPLC. For all 4 drugs there is a plateau at 10-30 min; a similar broad peak at 5-20 min has been found after lower doses (0 5 ,umol/g) of 4 of these compounds (excluding Ro 05-9963) . Fig. 3(b) shows the corresponding radiobiological effect expressed as tumour growth delay for mice irradiated with 21*7 Gy at various intervals after i.v. administration of the drug. Zero time represents no drug administered. Increasing growth delay indicates radiosensitization. The maximum delaywas seenat 10-20 min for all 4 compounds. Based on this assessment after high doses, a 20 min interval was used when comparing radiosensitizing activity over a range of drug doses.
MISO and Ro 03-8799 were also administered by the i.p. route for comparison with i.v. admninistration. Time-course studies were not performed in this work, but previous experiments have established that a 40 min interval between i.p. injection and the midpoint of irradiatioin achieves optimum radiosensitization in this tumour (Denekamp, 1982) . Fig. 4 shows the pharmacokinetics of the 4 compounds (i.e. excluding the toxic Ro 31-0054) in blood, brain and tumour. The longest half-life in blood was seen for MISO (57 min), vhich was distributed fairly uniformly throughout the body; by 20 min the tumour and brain concentrations were similar to those in blood. Tumour levels at 20 min were higher than those in blood for the basic compounds. Ro is inversely proportional to the distribution coefficient, as might be expected for brain exclusion of liphophobic compounds. The tumour: blood ratio of the basic compounds is higher than that for MISO and Ro 03-9963, and correlates with pKa. However, concentrations of Ro 03-8799 were also raised to the same degree in brain (Table III) , fat, skeletal muscle, and liver (data not shown). The phenomenon is therefore one of concentration in alltissues rather than of selective uptake into tumours.
Toxicity was assessed by acute lethality (Table III compound by either route of administration; Ro 31-0052 was similar in toxicity to MISO, whereas Ro 03-8799 was twice as toxic as MISO. There was no obvious correlation between toxicity and brain exposure or blood half-life, but Ro 31-0054 was the most toxic compound (10 times more than MISO) and it showed a similar increase in distribution volume; this may indicate rapid uptake into critical tissues. Fig. 5 Fig. 6 and has been directly compared with the in vitro data from Fig.  1 (dashed lines) (Denekamp & Harris, 1975; Denekamp et al., 1980a) .
To ensure that an arbitrary choice of endpoint size did not bias the estimate of SER' (Denekamp & Harris, 1975; Begg, 1980) , the results were re-analysed using a range of endpoint sizes corresponding to a volume increase of 4-9-fold. Although it was found that tumours regrew at rates which varied with the growth delay induced by treatment, there was no significant difference in SER's measured at different endpoint sizes. Two comparisons of the sensitizers were made: by administered dose and by tumour concentration. On the basis of equimolar dose, no difference was seen between the 5 compounds (Fig. 5) . Pharmacokinetic differences mean that the basic compounds achieve lower tumour concentrations than MISO after equimolar dosage (Figs 3 & 4, Table III), and radiosensitizing efficiency was therefore compared on the basis of tumour concentration. Fig. 6 shows that the basic compounds were up to 4 times as potent as MISO. This is close to the prediction of a factor of 3 based on the physicochemical parameter electron-affinity, but is much less than the 10-fold increase in potency seen with V79 cells in vitro (Smithen et al., 1980) , a discrepancy which is explained below. At low concentrations, equivalent to those achieved clinically with MISO, the SER' would only increase from 1-2 to 1P3; such a small difference would not be detectable in these experiments.
The accuracy of measurements of both drug concentration in tumours and the observed SER' determines the reliability of estimates of relative efficiency of the 5 compounds. The large error bars in Fig. 3 show that the HPLC estimate of Ro 03-8799 concentration in individual tumours was more variable than for the other compounds. Because of this, and because of the clinical interest in Ro 03-8799, a complete repeat of this pharmacology experiment was performed; blood and tumour concentrations raised up to 2-fold. The reason for this greater variability with Ro 03-8799 is not understood, but the conclusions remain unchanged whichever set of data is used. The estimates of SER' did not differ significantly in a repeat experiment (Figs 5 & 6) and the errors were certainly small enough to have detected the 10-fold difference in potency predicted from the in vitro data.
The discrepancy between the in vivo and in vitro results can be explained, because the concentration of a compound at its site of action is affected by its physicochemical and pharmacological properties. Both the in vitro data in Fig. 1 and the tumour data in Fig. 6 are expressed in terms of the gross concentration of drug, either in the medium surrounding the cells or in the homogenate made from tumours. Whilst these seem reasonable estimates, neither is a direct measure of intracellular drug concentration. Because charged molecules cross membranes relatively poorly (La Du et al., 1971 ) the distribution of basic compounds is pH-dependent. This principle of ion trapping was one reason these compound were thought to have clinical potential (Wardman, 1982) , both because they should be poorly reabsorbed from an acid urine, and because they might accumulate in the acidic regions shown to exist in tumours (Vaupel et al., 1981) . The 3 charged compounds have short half-lives as predicted, but the influence of pH on efficiency depends on whether the critical hypoxic cells themselves are internally acidic or whether there is simply a fall in extracellular pH. If there were concentration within hypoxic acidic cells in tumours, the basic compounds would be expected to be even more efficient in tumours than in vitro, which they clearly are not. Conversely, these drugs would accumulate extracellularly if the interstitial fluid were acidic but, unless such regions are a very lare proportion of the tumour, gross concentrations would closely parallel those in the critical hypoxic cells.
A pH-dependent change in the sensitizing efficiency of Ro 03-8799 in vitro has been reported for hypoxic V79 cells (Watts & Jones, 1981) . The SER for 0*1 mm fell from 1-54 to 1-33 when the extracellular pH was reduced from 7-4 to 6-5. Recent measurements of intracellular concentrations of Ro 03-8799 as a function of extracellular pH have shown that this change in SER can be explained by changes in intracellular drug levels (Clarke et al., 1982) . Somewhat surprisingly, the concentration of Ro 03-8799 at pH 7*4 (at 25°C) was found to be twice that in the surrounding medium. With MISO, the intracellular concentration was only 5000 of that in the medium. This differential concentration in vitro explains most, if not all, of the unexpectedly high efficiency of these basic compounds. Thus radiosensitizing efficiency measured in vivo agrees closely with that measured in vitro, when the basis of comparison is the intracellular concentration of each compound. The in vitro data, expressed in terms of the concentration in medium, were overoptimistic, and the 3-fold increase in efficiency predicted for these 3 basic compounds from electron-affinity fits both the corrected in vitro data and the present tumour results. This intracellular concentration of Ro 03-8799 at physiological pH would also explain the fact that the charged compounds achieved higher tumour: blood ratios than MISO at 20-30 min (Fig. 4, Table III ). This concentration effect correlates with pKa (Table I) and was also observed in other tissues with Ro 03-8799.
The improvement in radiosensitizing efficiency which we have observed in vivo with the basic compounds is slight, and any substantial clinical advantage would depend on reduced toxicity in man (i.e. the ability to administer a total of > 12 g/m2 during a course of radiotherapy). Our toxicity data are limited to acute lethality and sensitizer concentrations in mouse brains. Table III shows that Ro 03-8799 is more toxic than MISO in mice, when judged by lethality, but less toxic if judged by the AUC for brain; Ro 05-9963 is the least toxic of all and Ro 31-0052 is the least toxic of the 3 basic compounds. However, this assessment bears no direct relationship to the presumptive limiting toxicity in man: peripheral neurotoxicity. Brown & Workman (1980) have suggested that neurotoxicity might be reduced by lowering the lipophilicity of compounds by structural modification, in order to reduce drug entry into nervous tissue. As they predict, brain exposure (assessed on the basis of AUC) is correlated with distribution coefficient (Tables I & III) (Table III) , we know that these 2 drugs are equally toxic for peripheral neuropathy in man (Dische et al., 1981; Coleman et al., 1982) . Unfortunately, no laboratory assay in rodents has correctly ranked MISO, Ro 05-9963 and metronidazole, the neurotoxic dose limits of which have all been established in man (Hirst et al., 1979; Clarke et al., 1980; Conroy et al., 1980; Brown et al., 1981) . The selection of compounds for extensive animal toxicology before clinical trial therefore remains arbitrary.
The toxicity of Ro 03-8799 has been comprehensively examined in rats and monkeys, with daily i.v. injections over 4 weeks (M. R. Jackson, personal communication). The results with Cynomolqus monkeys, when compared with previous experience with MISO in this species, show that considerably larger doses of Ro 03-8799 are tolerated, the limiting toxicity being liver damage rather than neurotoxicity. This finding has encouraged Phase I clinical trials to be undertaken with Ro 03-8799 (Dische et al., 1982) .
The overall enhancement seen with MISO or any potential successor will be much less in clinical use than in the results obtained with large single doses of drug and X-rays in mice. Any reoxygenation will markedly diminish the gain there might otherwise be. The use of small X-ray doses per fraction will further reduce the observed SER', because oxic cells will dominate the response unless reoxygenation is very poor (Denekamp et al., 1980b; Durand & Olive, 1981; Denekamp & Joiner, 1982) . Nevertheless, sensitization has been found in human tumours treated with 9-10 fractions of irradiation (Urtasun et al., 1977; Ash et al., 1979) . The presence of hypoxic cells in human tumours is now well documented, and their persistence for at least 10 fractions in some tumours is indicated.
Before randomized clinical trials of a new compound to replace MISO are initiated, a marked gain in sensitization needs to be demonstrated in vivo. The present results are conisistent with a 3-4-fold increase in potency of the basic compounds relative to MISO, but at low, clinically relevant, concentrations, the improvement in SER' one would then expect is very small, and will be less still if the pharmacokinetics in mouse and man are similar (i.e. if tumour levels of Ro 03-8799 are lower than those after an equimolar dose of MISO). Any substantial advantage would depend on reduced toxicity in man; the primate toxicology results obtained with Ro 03-8799 are encouraging in this respect.
